Infliximab biosimilar (Amgen)

英夫利昔单抗生物类似药（安进）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInfliximab biosimilar (Amgen)
Drug Alias NameInfliximab-axxq英夫利昔单抗生物仿制药（安进）AvsolaABP-710
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPediatric ulcerative colitisCrohn Disease +[8] 
Global Approved IndicationsPlaque psoriasisPediatric ulcerative colitisCrohn Disease +[8] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/12/06
Country/TerritoryCzechiaBulgariaCanada +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmgen Inc
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPediatric ulcerative colitisCrohn Disease +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB02
Related LinksWikipediaDrugBankKEGG